Shots:
- Verge to receive ~$25M as up front, equity investment, and near-term payments in addition to ~$694M as milestone and royalties
- The collaboration will utilize Verge’s AI-driven all-in-human platform to identify new targets. Lilly may select up to four identified targets to advance it into clinical development and commercialization
- Verge Genomics retains all rights to its lead program & plans to start clinical trials for its lead program that targets PIKfyve for ALS in 2022
Click here to read full press release/ article | Ref: Businesswire | Image: Venture Beat
The post Lilly Signs a Three-Year Collaboration with Verge Genomics to Discover and Develop Novel Therapies for ALS first appeared on PharmaShots.
